


Supplementary Figure 7



**Figure S7:** Safety of the treatments with EGFR-targeted scTRAIL fusion proteins and Fc-scTRAIL in combination with bortezomib. Potential toxicity was evaluated by measuring ALT and amylase activity in serum samples collected 4 h and 24 h after the first and the last treatment of the *in vivo* experiment shown in Figure 5A.